Jump to content

Talk:David Rees (organic chemist)

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

I need to change this page to David Rees (chemist) to disambiguate from other David Rees pages

I've also now noticed that a redirect page, 'David Rees (chemist)' exists. So maybe this page should be moved to 'David Charles Rees' and should be disambiguated on the David Rees page. Or the redirect page should be removed?

Notability - NACADEMIC

[edit]

While Rees doesn't appear to pass GNG, he does pass multiple criteria of WP:NACADEMIC, primarily criterion 3 but also criterion 1. Nosebagbear (talk) 19:26, 3 September 2019 (UTC)[reply]


Scitribe (talk) 04:23, 19 June 2021 (UTC) == Update request == I would like to update David's page with newer and/or missing information about him and his career, at his request. I can confirm that he is happy himself with all of the information provided. I look forward to hearing from Wikipedia Admin about this. If this is okay then I can upload to David's Wikipedia page, unless you would do this. Please let me know. Thank you, Scitribe.[reply]

1. In the information box it's missing his "letters" CChem FRSC FMedSci.

2. In the information box it's missing some of his recent awards.

RSC BMCS Hall of Fame (2020) [1] Royal Society of Chemistry BMCS Lectureship 2021/2022 [2]

3. To organise the body of David's entry to introduce him and then provide information about his career, fellowships and further reading in clear, distinct paragraphs and sections. Also updated the information. See below:

David Charles Rees (born 1958) CChem FRSC FMedSci is a chemist recognised internationally for his innovative use of chemistry in drug discovery.[3] He is Chief Scientific Officer of biotechnology company Astex Pharmaceuticals, which is located in Cambridge, UK.

Career David joined Astex in 2003 to lead its chemistry team. He became Chief Scientific Officer (CSO) in 2017.[5] In 2013, Astex was acquired for around USD $900 million [12] and now operates as a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd, headquartered in Tokyo, Japan.

Rees is associated with the discovery of three launched drugs: ribociclib (Astex-Novartis collaboration),[6] erdafitinib (Astex-Janssen collaboration)[7] as well as the anaesthetic reversal agent sugammadex (Organon, Merck),[8] which has been used in over 30 million patients in 60 countries and had global sales of US$1.2 billion in 2020.[9]

Rees has a BSc from the University of Southampton and PhD from the University of Cambridge.

Fellowships, Awards, and Academic Appointments David is a Fellow of the Royal Society of Chemistry. He is one of the few industrial scientists to have served as President of its Organic Division (2010-2013), and was later elected to the RSC Board of Trustees (2015-2019).[10]

Rees has held visiting professorships at three UK universities, and sits on several scientific advisory boards for not-for-profit organisations. In 2020 he was elected as a Fellow of the Academy of Medical Sciences and inducted into the RSC BMCS Hall of Fame [13]. He has over 140 publications and patents.

Rees is also a Director of Ashanti Development, a charity that promotes clean water and sanitation in Ghana.[11]

More reading David Charles Rees. Astex website. https://astx.com/portfolio-item/david-rees. Retrieved 26 May 2021. Accessed 26 May 2021.

4. References updated/re-arranged to match updated text in #3.

References 1. "BMCS Malcolm Campbell Award". Retrieved 2019-04-30. 2. ^ "e-theses online service". Retrieved 2019-04-30. 3. ^ "david rees - Google Scholar Citations". scholar.google.co.uk. Retrieved 2019-04-24. 4. ^ "Astex – Oncology and CNS Drug Discovery & Development". Retrieved 2019-04-24. 5. ^ "David Rees – Astex". Retrieved 2019-04-24. 6. ^ Bickerton, Peggy. "Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval – Astex". Retrieved 2019-04-24. 7. ^ webadmin. "Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval – Astex". Retrieved 2019-04-24. 8. ^ Bom, Anton; Bradley, Mark; Cameron, Ken; Clark, John K.; Egmond, Jan van; Feilden, Helen; MacLean, Elizabeth J.; Muir, Alan W.; Palin, Ronald (2002). "A Novel Concept of Reversing Neuromuscular Block: Chemical Encapsulation of Rocuronium Bromide by a Cyclodextrin-Based Synthetic Host". Angewandte Chemie International Edition. 41 (2): 265–270. doi:10.1002/1521-3773(20020118)41:2<265::AID-ANIE265>3.0.CO;2-Q. ISSN 1521-3773. 9. ^ "Merck & Co., Inc. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2018" (PDF). 10. ^ "The Royal Society of Chemistry - our structure". www.rsc.org. Retrieved 2019-04-24. 11. ^ "Our Team in the UK". Ashanti Development. Retrieved 2019-04-24. 12. "Japan's Otsuka to buy Astex Pharma for about $900 million: Nikkei". Reuters. 4 September 2013. Retrieved 14 April 2021. 13. BMCS Hall of Fame and Medal. RSCBMCS website. https://www.rscbmcs.org/awards/halloffame/ Accessed 26 May 2021.

5. I have a new photo of David which he is happy with Wikipedia using and which fulfil the copyright requirements.Scitribe (talk) 04:23, 19 June 2021 (UTC)[reply]

References

Updates to profile from David Charles Rees

[edit]

Scitribe (talk) 06:10, 21 June 2021 (UTC)Scitribe (talk) 04:23, 19 June 2021 (UTC) == Update request == I would like to update David's page with newer and/or missing information about him and his career, at his request. I can confirm that he is happy himself with all of the information provided. I look forward to hearing from Wikipedia Admin about this. If this is okay then I can upload to David's Wikipedia page, unless you would do this. Please let me know. Thank you, Scitribe.[reply]

1. In the information box it's missing his "letters" CChem FRSC FMedSci.

2. In the information box it's missing some of his recent awards.

RSC BMCS Hall of Fame (2020) [1] Royal Society of Chemistry BMCS Lectureship 2021/2022 [2]

3. To organise the body of David's entry to introduce him and then provide information about his career, fellowships and further reading in clear, distinct paragraphs and sections. Also updated the information. See below:

David Charles Rees (born 1958) CChem FRSC FMedSci is a chemist recognised internationally for his innovative use of chemistry in drug discovery.[3] He is Chief Scientific Officer of biotechnology company Astex Pharmaceuticals, which is located in Cambridge, UK.

Career David joined Astex in 2003 to lead its chemistry team. He became Chief Scientific Officer (CSO) in 2017.[5] In 2013, Astex was acquired for around USD $900 million [12] and now operates as a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd, headquartered in Tokyo, Japan.

Rees is associated with the discovery of three launched drugs: ribociclib (Astex-Novartis collaboration),[6] erdafitinib (Astex-Janssen collaboration)[7] as well as the anaesthetic reversal agent sugammadex (Organon, Merck),[8] which has been used in over 30 million patients in 60 countries and had global sales of US$1.2 billion in 2020.[9]

Rees has a BSc from the University of Southampton and PhD from the University of Cambridge.

Fellowships, Awards, and Academic Appointments David is a Fellow of the Royal Society of Chemistry. He is one of the few industrial scientists to have served as President of its Organic Division (2010-2013), and was later elected to the RSC Board of Trustees (2015-2019).[10]

Rees has held visiting professorships at three UK universities, and sits on several scientific advisory boards for not-for-profit organisations. In 2020 he was elected as a Fellow of the Academy of Medical Sciences and inducted into the RSC BMCS Hall of Fame [13]. He has over 140 publications and patents.

Rees is also a Director of Ashanti Development, a charity that promotes clean water and sanitation in Ghana.[11]

More reading David Charles Rees. Astex website. https://astx.com/portfolio-item/david-rees. Retrieved 26 May 2021. Accessed 26 May 2021.

4. References updated/re-arranged to match updated text in #3.

References 1. "BMCS Malcolm Campbell Award". Retrieved 2019-04-30. 2. ^ "e-theses online service". Retrieved 2019-04-30. 3. ^ "david rees - Google Scholar Citations". scholar.google.co.uk. Retrieved 2019-04-24. 4. ^ "Astex – Oncology and CNS Drug Discovery & Development". Retrieved 2019-04-24. 5. ^ "David Rees – Astex". Retrieved 2019-04-24. 6. ^ Bickerton, Peggy. "Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval – Astex". Retrieved 2019-04-24. 7. ^ webadmin. "Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval – Astex". Retrieved 2019-04-24. 8. ^ Bom, Anton; Bradley, Mark; Cameron, Ken; Clark, John K.; Egmond, Jan van; Feilden, Helen; MacLean, Elizabeth J.; Muir, Alan W.; Palin, Ronald (2002). "A Novel Concept of Reversing Neuromuscular Block: Chemical Encapsulation of Rocuronium Bromide by a Cyclodextrin-Based Synthetic Host". Angewandte Chemie International Edition. 41 (2): 265–270. doi:10.1002/1521-3773(20020118)41:2<265::AID-ANIE265>3.0.CO;2-Q. ISSN 1521-3773. 9. ^ "Merck & Co., Inc. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2018" (PDF). 10. ^ "The Royal Society of Chemistry - our structure". www.rsc.org. Retrieved 2019-04-24. 11. ^ "Our Team in the UK". Ashanti Development. Retrieved 2019-04-24. 12. "Japan's Otsuka to buy Astex Pharma for about $900 million: Nikkei". Reuters. 4 September 2013. Retrieved 14 April 2021. 13. BMCS Hall of Fame and Medal. RSCBMCS website. https://www.rscbmcs.org/awards/halloffame/ Accessed 26 May 2021.

5. I have a new photo of David which he is happy with Wikipedia using and which fulfil the copyright requirements.Scitribe (talk) 04:23, 19 June 2021 (UTC) Scitribe (talk) 06:10, 21 June 2021 (UTC)[reply]